Alnylam Pharmaceuticals (ALNY) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $280.76 +0.96%
EPS Growth %: +409.4%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- CarMax (KMX) Tops Q1 EPS by 35c, Beats on Revenue
- Vince Holding (VNCE) Tops Q1 EPS by 21c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
